Patau Syndrome (Trisomy 13)
Patau Syndrome, also known as Trisomy 13, is a chromosomal condition caused by an additional copy of chromosome 13. Prenatal screening, detailed ultrasound and appropriate genetic testing can help identify pregnancies with an increased chance of Trisomy 13 and provide families with clear information about further evaluation.
Patau Syndrome is a genetic condition caused by an extra copy of chromosome 13. It is also called Trisomy 13. The additional chromosome can affect the development of multiple organs and body systems during pregnancy.
Trisomy 13 can sometimes be suspected during pregnancy when ultrasound findings or prenatal screening indicate an increased chance of a chromosomal abnormality. However, an ultrasound finding or screening result alone does not establish a definite diagnosis.
First-trimester assessment may include an ultrasound examination with nuchal translucency measurement, fetal anatomical assessment, maternal factors and blood-based screening. These findings can contribute to risk assessment for common chromosomal conditions, including Trisomy 13.
Nuchal translucency, or NT, is a measurement of fluid at the back of the fetal neck obtained during a specialized first-trimester ultrasound. An increased NT can be associated with chromosomal conditions, including Trisomy 13, as well as certain structural and cardiac abnormalities. An increased NT by itself does not confirm Patau Syndrome.
Non-Invasive Prenatal Testing, also called NIPT, NIPS or cell-free DNA screening, uses a blood sample from the pregnant woman to analyse DNA fragments originating mainly from the placenta. Cell-free DNA screening can assess the chance of common chromosomal conditions, including Trisomy 13.
NIPT is a highly sensitive screening method for common fetal aneuploidies, including Trisomy 13. A high-risk result indicates an increased chance rather than a confirmed diagnosis. A positive screening result should be followed by appropriate counselling, detailed ultrasound assessment and discussion of diagnostic testing such as CVS or amniocentesis.
Detailed fetal ultrasound may identify structural findings associated with Trisomy 13. Possible findings can involve the brain, face, heart, limbs, kidneys, abdominal wall and other organs. The presence and severity of findings can vary between pregnancies, so ultrasound assessment should be performed by an experienced fetal medicine specialist.
Some pregnancies affected by Trisomy 13 may show abnormalities involving brain development or facial structures. Findings such as holoprosencephaly, facial clefting or other developmental abnormalities may raise suspicion during an ultrasound examination. These findings require detailed assessment and appropriate counselling.
Congenital heart abnormalities can occur in fetuses with Trisomy 13. When a chromosomal condition is suspected, a detailed assessment of the fetal heart may form an important part of the ultrasound evaluation. In selected pregnancies, a dedicated fetal echocardiography may also be recommended.
Depending on the pregnancy, ultrasound may identify abnormalities involving fetal growth, kidneys, limbs, abdominal structures or other organs. Multiple structural findings can increase suspicion for an underlying chromosomal condition and may lead to a recommendation for further genetic evaluation.
Ultrasound can identify findings that increase the suspicion of Trisomy 13, but ultrasound alone cannot provide a definitive chromosomal diagnosis. A normal ultrasound also cannot completely exclude a chromosomal condition. Screening and diagnostic testing should therefore be considered according to the individual pregnancy and clinical findings.
Diagnostic testing can determine whether the fetus has a chromosomal abnormality. Chorionic villus sampling (CVS) and amniocentesis are diagnostic procedures that obtain placental or amniotic cells for chromosome analysis. Testing options and timing are discussed individually with the parents.
Chorionic villus sampling involves obtaining a small sample of placental tissue for genetic testing. It can provide diagnostic information about chromosomal conditions such as Trisomy 13. The procedure is performed under ultrasound guidance and is discussed with the parents after considering the benefits, limitations and small procedure-related risks.
Amniocentesis involves obtaining a small sample of amniotic fluid for genetic analysis. It is a diagnostic test that can be used to investigate suspected chromosomal abnormalities, including Trisomy 13, when clinically appropriate.
A high-risk NIPT result for Trisomy 13 does not automatically mean that the fetus has Patau Syndrome. The result should be reviewed with a fetal medicine specialist or genetic counsellor. Detailed ultrasound and diagnostic testing may be recommended to establish whether the chromosomal condition is actually present.
A low-risk NIPT result substantially reduces the chance of the screened chromosomal conditions, including Trisomy 13, but does not exclude every genetic or structural condition. Recommended ultrasound examinations and routine pregnancy care remain important.
A detailed second-trimester anomaly scan evaluates the baby's brain, face, spine, heart, abdomen, limbs, kidneys, placenta, amniotic fluid and overall growth. This examination is important even when prenatal genetic screening has been performed because structural abnormalities may occur independently of a chromosomal abnormality.
Screening for Trisomy 13 can also be considered in twin pregnancies. However, the interpretation of screening results can differ from singleton pregnancies. An individualized assessment is important, particularly when there are ultrasound abnormalities, a vanishing twin or other pregnancy-specific factors.
Genetic counselling helps parents understand the difference between screening and diagnostic testing, the meaning of ultrasound findings, possible testing options and the limitations of each test. Counselling can be particularly valuable when screening or ultrasound suggests an increased chance of Trisomy 13.
When diagnostic testing confirms Trisomy 13, parents can receive detailed counselling about the findings, pregnancy monitoring, fetal condition and available care options. Management is individualized according to the pregnancy, ultrasound findings, gestational age and the family's informed preferences.
Early fetal medicine assessment can help identify concerning ultrasound findings and provide timely access to screening, diagnostic testing and specialist counselling. A structured evaluation allows parents to understand the available information and make informed decisions regarding their pregnancy care.
At Promise Fetal Medicine & Pregnancy Scan Centre in Jalandhar, prenatal assessment for suspected Trisomy 13 may include specialized ultrasound, nuchal translucency assessment, NIPT counselling, detailed anomaly scanning and guidance regarding appropriate diagnostic genetic testing.
If you have received an abnormal ultrasound finding, a high-risk NIPT result or another screening result suggesting Trisomy 13, a fetal medicine consultation can help you understand the findings and available next steps. Specialist assessment can provide individualized information and support throughout the pregnancy.
Ensure Your Baby’s Health with Expert Fetal Care and Advanced Sonography
Book Your Consultation Today for a Safe and Healthy Pregnancy
Patau syndrome, also known as Trisomy 13, is a chromosomal condition caused by the presence of an extra copy of chromosome 13. It can affect the development of the brain, heart, face, limbs, and other organs. During pregnancy, screening methods such as NIPT (Cell-Free DNA), first-trimester screening, and detailed fetal ultrasound can help assess the likelihood of Trisomy 13. At Promise Fetal Medicine & Pregnancy Scan Centre in Jalandhar, detailed ultrasound assessment and appropriate prenatal screening can help identify pregnancies that may require further evaluation and counseling. Screening tests estimate risk and do not confirm Patau syndrome; diagnostic testing may be recommended when indicated.
Director and Chief Fetal Medicine Specialist
Baby's Journey Through Pregnancy
